Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Show Me the Value

This article was originally published in RPM Report

Executive Summary

As cancer drug prices approach $100,000, manufacturers are facing strong resistance from manufacturers. Now Wall Street is starting to worry.

You may also be interested in...



Medicare Research Priorities: A Taste Of What's To Come?

Any government-sponsored center on comparative effectiveness will focus on the research priorities of the Medicare and Medicaid programs as a way to lower health care costs. The findings of a Medicare coverage advisory committee offers a glimpse of where those priorities may fall.

Reimbursing Designer Drugs

Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.

Reimbursing Designer Drugs

Now that FDA is pushing a regulatory pathway for personalized medicine through the Critical Path initiative, the next step for industry should be securing payment, especially given what could be relatively high price tags. So what are payors--and the biggest payor of all, CMS--doing to prepare? The answer is, not much.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS080075

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel